CHRS — Coherus Oncology, Inc.

Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue Growth: LOQTORZI net revenue reached $40.8 million for the full year 2025, up 113% from $19.1 million in 2024. Q4 revenue was $12.4 million, reflecting an 11% increase over Q3.
• Debt Reduction: The company reduced its secured and convertible debt by over 90%, from $480 million to $38.8 million by year-end 2025, significantly lowering interest costs.
• Operating Expenses: SG&A expenses decreased to $23.6 million in Q4 from $29.6 million in Q4 2024. R&D expenses increased to $31 million in Q4 2025, up from $20.8 million in the same quarter the previous year.
• Cash Position: Cash equivalents and investments totaled $172.1 million at year-end.

2. Strategic Updates and Business Highlights

• Transformation: Coherus has transitioned from a biosimilar-focused company to an innovative oncology firm, highlighted by the acquisition of Surface Oncology and the development of two promising assets: tagmokitug and casdozokitug.
• Product Launch: LOQTORZI, a next-gen PD-1 inhibitor, was launched in 2024 and is positioned as the only approved treatment for recurrent, locally advanced, or metastatic nasopharyngeal carcinoma (NPC) in the U.S.
• Clinical Development: The company is advancing its clinical programs, with multiple trials for tagmokitug and casdozokitug expected to yield initial data by mid-2026.

3. Forward Guidance and Outlook

• Revenue Projections: Coherus anticipates LOQTORZI will achieve peak annual revenues of approximately $175 million by 2028, with a target of reaching $15-16 million in quarterly sales by 2026 and $30-35 million by 2027.
• Clinical Milestones: Initial data readouts for ongoing clinical trials are expected in mid-2026, which will inform further development strategies and potential partnerships.

4. Challenges and Points of Concern

• Market Competition: The Treg depletion field is becoming increasingly competitive, necessitating strategic investments and partnerships to maintain a leading position.
• Sales Sensitivity: LOQTORZI's sales are highly promotion-sensitive, requiring continuous physician engagement to drive new patient starts, particularly in a rare disease market.
• Operational Efficiency: The company has reduced its workforce significantly, which could impact operational capacity and development speed.

5. Notable Q&A Insights

• Patient Dynamics: Approximately 25% of LOQTORZI's revenue in 2025 came from new patients, with expectations for this mix to shift towards more new patients as the company expands its marketing efforts.
• Promotional Strategies: The company is investing in commercial infrastructure, including a modest expansion of the sales force and enhanced IT capabilities to capture patient opportunities.
• Clinical Data Disclosure: Future data releases will depend on patient accrual and scan timelines, with a commitment to transparency as data becomes available.
• Combination Therapies: There is interest in exploring triple combinations involving tagmokitug, with ongoing evaluations of its efficacy alongside other treatments.

Overall, Coherus Oncology is positioned for growth with a strong focus on innovative oncology products and a solid financial foundation, though it faces competitive pressures and the need for effective promotional strategies to maximize its market potential.